Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
News in Skin Diseases: From Basic Mechanisms to Therapies
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

News in Skin Diseases: From Basic Mechanisms to Therapies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 1345

Special Issue Editor

Dr. Takemichi Fukasawa

E-Mail Website
Guest Editor
Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
Interests: systemic sclerosis; psoriasis; atopic dermatitis; myositis; SLE; vasculitis; B cells; T cells
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, advances have been made in the treatment of various inflammatory skin diseases that cause skin lesions, such as psoriasis, atopic dermatitis, and scleroderma. Many biologics targeting inflammatory cytokines and molecularly targeted drugs, such as JAK inhibitors, have emerged. The mechanisms of action and research on these drugs are advancing at a tremendous pace. These treatments are being studied from a variety of perspectives, including not only their therapeutic effect on skin lesions, but also their therapeutic effect on joints and their impact on other complications. In this Special Issue of IJMS, we will publish cutting-edge information regarding recent advances in the research of skin diseases from molecular viewpoints. We warmly welcome research and review articles concerning a variety of factors relating to skin diseases, including their genetic/epigenetic regulation, therapy, and prevention. In this Special Issue, we aim to present the latest findings regarding skin diseases, from basic mechanisms to therapies.

Dr. Takemichi Fukasawa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • skin diseases
  • psoriasis
  • atopic dermatitis
  • scleroderma
 

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

22 pages, 5296 KiB  
Article
Skin Anti-Inflammatory Potential with Reduced Side Effects of Novel Glucocorticoid Receptor Agonists
by Enrica Flori, Sarah Mosca, Daniela Kovacs, Stefania Briganti, Monica Ottaviani, Arianna Mastrofrancesco, Mauro Truglio and Mauro Picardo
Int. J. Mol. Sci. 2024, 25(1), 267; https://doi.org/10.3390/ijms25010267 - 23 Dec 2023
Viewed by 952
Abstract
Glucocorticoids (GCs) are commonly used in the treatment of inflammatory skin diseases, although the balance between therapeutic benefits and side effects is still crucial in clinical practice. One of the major and well-known adverse effects of topical GCs is cutaneous atrophy, which seems [...] Read more.
Glucocorticoids (GCs) are commonly used in the treatment of inflammatory skin diseases, although the balance between therapeutic benefits and side effects is still crucial in clinical practice. One of the major and well-known adverse effects of topical GCs is cutaneous atrophy, which seems to be related to the activation of the glucorticoid receptor (GR) genomic pathway. Dissociating anti-inflammatory activity from atrophogenicity represents an important goal to achieve, in order to avoid side effects on keratinocytes and fibroblasts, known target cells of GC action. To this end, we evaluated the biological activity and safety profile of two novel chemical compounds, DE.303 and KL.202, developed as non-transcriptionally acting GR ligands. In primary keratinocytes, both compounds demonstrated anti-inflammatory properties inhibiting NF-κB activity, downregulating inflammatory cytokine release and interfering with pivotal signaling pathways involved in the inflammatory process. Of note, these beneficial actions were not associated with GC-related atrophic effects: treatments of primary keratinocytes and fibroblasts with DE.303 and KL.202 did not induce, contrarily to dexamethasone—a known potent GC—alterations in extracellular matrix components and lipid synthesis, thus confirming their safety profile. These data provide the basis for evaluating these compounds as effective alternatives to the currently used GCs in managing inflammatory skin diseases. Full article
(This article belongs to the Special Issue News in Skin Diseases: From Basic Mechanisms to Therapies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop